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Introduction
 Hepatitis B virus (HBV) is a human carcinogen and 
chronic infection still remains as a major global health 
problem. Approximately a third of the world’s population 
(2 billion people) has been infected with this virus and 
more than 350 million of them are chronically infected 
cases. Long term sequelae as cirrhosis, liver failure and 
hepatocellular carcinoma lead to 600,000-1000000 deaths 
annually (Custer et al., 2004; Lavanchy, 2004). Hepatitis 
C virus (HCV) is also one of the main causes of chronic 
liver diseases. The long term impact of HCV is highly 
variable as in HBV infection. The number of chronically 
infected cases is estimated to be more than 200 million 
worldwide (EASL, 2011). In Turkey, the seropositivity of 
Hbs ag has been reported as 3.4% in the western region; 
while as 8% in eastern and southeastern regions (Mehmet 
et al., 2005). Gurol et al documented the trends over 16 
years in HBV and HCV seroprevalence among 2.4 million 
Turkish blood donors. They have reported that the overall 
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Abstract
 Background: Hepatitis B and C are the leading causes of liver diseases worldwide. For hematological and solid 
malignancy patients undergoing chemotherapy, increases in HBV DNA and HCV RNA levels can be detected 
which may result in reactivation and hepatitis-related morbidity and mortality. The aim of this study was to 
determine the seroprevalence of Hbs ag and Anti HCV positivity in patients with solid malignancies undergoing 
chemotherapy and consequences during follow-up. Materials and Methods: The files of 914 patients with solid 
malignancies whose hepatitis markers were determined serologically at diagnosis were reviewed retrospectively. 
All underwent adjuvant/palliative chemotherapy. For the cases with HBV and/or HCV positivity, HBV DNA 
and HCV RNA levels, liver function tests at diagnosis and during follow-up and the treatment modalities that 
were chosen were determined. Results: Of 914 cases, Hbs Ag, anti Hbs and anti HCV positivity were detected 
in 40 (4.4%), 336 (36.8%) and 26 (2.8%) of the cases respectively. All of the Hbs ag positive patients received 
prophylactic lamuvidine before the start of chemotherapy. In the Hbs ag and anti HCV positive cases, liver 
failure was not detected during chemotherapy and a delay in chemotherapy courses because of hepatitis was 
not encountered. Conclusions: Just as with hematological malignancies, screening for HBV and HCV should 
also be considered for patients with solid tumors undergoing chemotherapy. Prophylactic antiviral therapy for 
HBV reduces both the reactivation rates and HBV related mortality and morbidity. The clinical impact of HCV 
infection on patients undergoing chemotherapy is still not well characterized. 
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prevalence was 4.19% for Hbs ag and 0.38% for HCV 
in Turkey (Gurol et al., 2006). In another study among 
healthcare workers, the prevalence of HCV was reported 
as between 1.2-4% (Yazici et al., 2010). 
 Since chemotherapy is highly immunosuppressive, it 
may cause increments in both HBV DNA and HCV RNA 
levels. For HBs Ag carriers the flares can occur despite 
normal serum alanine transferase (ALT) levels and low 
levels of circulating viral load and this leads to HBV 
related mortality and morbidity (Lau et al., 2003; Kohrt 
et al., 2006). For Hbs Ag seropositive cancer patients 
undergoing chemotherapy, HBV reactivation has been a 
well known complication, which may range from anicteric 
hepatitis to severe and sometimes fatal hepatic failure 
(Alagozlu et al., 2013). In 1990s, the reports about HBV 
reactivation mostly involved patients with hematologic 
malignancies (Soh et al., 1992; Nakamura et al., 1996; 
Kumagai et al., 1997). More recently, studies have 
reported reactivation in solid tumors as well, especially 
in breast cancer patients (Alexopoulos et al., 1999; Yeo 
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et al., 2003). High HBV viral load before chemotherapy, 
Hbe ag positivity, male gender, young age, lymphoma or 
breast cancer as primary malignancy have been thought 
as probable risk factors for reactivation of Hepatitis B 
(Steinberg et al., 2000; Yeo et al., 2000). Over the past 
decade, it has been recognized that HBV reactivation 
risk during chemotherapy can be dismissed by the use of 
prophylactic lamuvidine. 
 The levels of HCV viral RNA has also been shown 
to increase while on chemotherapy in some case 
reports, however, case series review failed to find such 
complication common (Kanamori et al., 1992; Vento et 
al., 1996; Zuckerman et al., 1998). In a recent review 
it was reported that, after the rise by chemotherapy, 
upon the withdrawal of immunosuppressant, HCV RNA 
levels decrease with a concomitant rise in ALT levels 
which was explained by the suppression of immunity by 
chemotherapy and a rebound of reaction towards hepatitis 
C by its withdrawal (Hwang and Liang, 2010). However, 
unlike Hepatitis B, the impact of chronic HCV infection 
on patients undergoing chemotherapy is still not well 
defined.
 In this study we aimed to determine the seroprevalence 
of Hepatitis B and C in patients with solid malignancies 
and also evaluate the follow up of liver functions in the 
seropositive group during chemotherapy, whether any 
reactivation has occurred or not.
Materials and Methods
 The files of 990 patients with a diagnosis of solid 
malignancy, which were confirmed pathologically and 
were given adjuvant and/or palliative chemotherapy 
and still are on follow-up in the department of Medical 
Oncology at Kayseri Education and Research Hospital, 
were evaluated retrospectively. The cases that were found 
to have serologically determined hepatitis markers at 
diagnosis were included in the study. A total of 914 files 
were included in the study. Demographical properties 
of the patients and the primary sites of the malignancies 
were recorded. For the cases with HBV and/or HCV 
positivity, HBV DNA and HCV RNA levels, liver function 
tests at diagnosis and during follow-up and the treatment 
modalities that were chosen were determined. 
Results 
 Of the 914 cases; 571 (62.5%) were female, 343 
(37.5%) were male and the median age was 56. The most 
common types of cancer detected were breast carcinoma 
in 402 (43.9%), gastric in 116 (12.7%), colorectal in 102 
(11.2%), lung in 73 (7.9%), genitourinary in 48 (5.3%) and 
renal cell carcinoma in 27 (2.9%) of the cases. The median 
number of chemotherapy cycles were 5 (range 4-8). Hbs 
Ag, Anti Hbs and Anti HCV positivity were detected 
in 40 (4.4%), 336 (36.8%) and 26 (2.8%) of the cases 
respectively. In the Hbs ag and Anti HCV seropositive 
patient group the most common cancer detected was 
breast carcinoma (14 and 12 cases respectively). In the 
Hbs ag positive group (n:40), 18 of them were shown to 
have detectable HBV DNA levels, while the rest 22 had 
negative HBV DNA levels. For all patients with Hbs ag 
positivity, prophylactic lamuvidine was administered a 
week before the start of chemotherapy till after the end 
of chemo, since all of them had adjuvant and/or palliative 
chemotherapy. During follow-up of these cases, liver 
function tests were all in acceptable levels. There were 
no interruptions in chemotherapy delivery because of 
hepatitis B and no side effect for lamuvidine was detected. 
Of these 18 HBV DNA positive cases, 2 cases with 
metastatic colon cancer having palliative chemotherapy 
together with lamuvidine, were shown to have HBV DNA 
negativity at the end of chemotherapy period. 
 In the Anti HCV positive group (n:26) 11 of them 
had detectable HCV RNA levels. One patient had been 
treated for HCV before the diagnosis of malignancy and 
his HCV RNA was negative from the start till the end of 
chemotherapy. Liver function tests of all the patients with 
HCV positivity were on regular follow-up and hepatic 
failure was not detected in any of them.
Discussion
Chemotherapy induced hepatitis reactivation may 
cause varying degrees of hepatic damage leading to 
disruption of chemotherapy and thereby compromising 
the cancer prognosis. So it is important to deal with the 
problem of hepatitis before the start of chemotherapy 
even in solid tumors to get the maximum benefit from 
chemotherapy.
In our study, HBs ag positivity was detected as 4.4% 
and Anti HCV positivity in 2.8% of patients with solid 
tumors. These are in concordance with the results in most 
of the studies from our country. Utkan et al. (2006) have 
reported that, in cancer patients the seropositivity of HBs 
ag and Anti HCV was 4.8% and 2.8% respectively. Kose 
et al (2011) examined hepatitis seroprevalence in 448 
patients with solid malignancy and reported positivity of 
HBs ag in 4.2% and anti HCV positivity in 0.7% of them. 
They have found no significant association between types 
of cancers and HBs ag and Anti HCV positivity. In the 
study of Kose et al. (2011), the seroprevalence of Hepatitis 
C was slightly lower than our study results, whereas 
Uzun et al. (2002) have reported that the prevalence of 
Anti HCV was 6.7% among lung cancer patients, which 
was significantly higher compared to Turkish population 
and also to our study results. In our study, in 3 of 73 lung 
cancer patients HBs ag was positive but none had Anti 
HCV positivity detected. 
In this study we also examined the effect of hepatitis 
B and C positivity during chemotherapy. In none of our 
patients with Hbs ag or Anti HCV positivity, liver failure 
or any delay in chemotherapy because of hepatitis was 
observed. In some of the patients, slight increases in 
transaminases were observed that were all below twice the 
upper normal limits and none had increases in bilirubin 
levels. 
In the early reports, the effect of the antiviral agent 
lamuvidine was studied in Hbs ag positive patients 
who experienced ALT elevation attributable to HBV 
reactivation. They have concluded that this approach 
has a role in controlling HBV reactivation during 
Asian Pacific Journal of Cancer Prevention, Vol 15, 2014 1413
DOI:http://dx.doi.org/10.7314/APJCP.2014.15.3.1411
Hepatitis B and C Seroprevalence in Solid Tumors - Screening During Chemotherapy
chemotherapy whereas still some fatal reactivations were 
also reported (Clark et al., 1998; Ter Borg et al., 1998; 
Cainelli et al., 2001). Later by serial monitoring of HBV 
DNA and ALT levels, it was shown that viral replication 
occurs 1-2 weeks before clinical picture of hepatitis 
occur in cancer patients receiving chemotherapy. Then a 
prophylactic strategy, as using lamuvidine before the start 
of chemotherapy for prevention of HBV reactivation and 
related morbidities and mortalities, has risen (Yeo and 
Johnson, 2006). The earlier reports about prophylactic 
lamuvidine were reported on hematological malignancies 
especially lymphoma patients. In the study of Persico et al 
(2002), 21 non-Hodgkin lymphoma patients with Hbs ag 
positivity were given chemotherapy and in 12 had hepatitis 
reaction, 9 of these were given lamuvidine and all were 
reported to recover. Another 3 patients were reported to 
have used lamuvidine from the beginning of chemo and 
they didn’t have any hepatitis reaction. They concluded 
that lamuvidine was a useful drug to both treat and prevent 
HBV reactivation in patients with non Hodgkin lymphoma 
that receive chemotherapy. 
Among solid tumors, the prevalence of hepatitis B and 
the effect of lamuvidine have been mostly studied in breast 
cancer patients. Yeo et al. (2004) in their retrospective 
trial, reported that prophylactic lamuvidine significantly 
reduced both the incidence of HBV reactivation from 
31% to 6.5 % and also the disruption of chemotherapy. 
In a prospective and randomized trial on breast cancer 
patients, it was shown that there was significantly less 
HBV reactivation in the prophylactic lamuvidine receiving 
group compared with the group receiving lamuvidine only 
after proven HBV reactivation during chemotherapy (p 
0.021). But the disruptions of chemotherapy and overall 
survival were the same for the two groups (Long et al., 
2011). In a systematic review that contains 14 studies on 
both hematological and solid tumors, it was concluded 
that preventive lamuvidine reduced the risk of HBV 
reactivation by approximately 80% and that all patients 
testing Hbs ag positive should be considered for preventive 
lamuvidine before the start of chemotherapy (Loomba 
et al., 2008). But the optimal duration of lamuvidine 
treatment is still not crucial. In our study, prophylactic 
lamuvidine was started for all Hbs ag positive patients, 
one week before the start of chemotherapy and it was 
continued for 6 months after the completion of chemo. 
In these 40 patients there were no HBV reactivation or 
hepatitis flare detected and no lamuvidine related side 
effects were observed. Besides in two of our cases, HBV 
DNA was levels were found to be negative at the end of 
chemotherapy, with lamuvidine treatment. 
Compared with hepatitis B, there is scanty data on 
management of Anti HCV positivity in cancer patients. 
The clinical impact of HCV infection on patients 
undergoing chemotherapy is not yet well characterized. 
There are conflicting evidence about the patients with 
HCV positivity and undergoing chemotherapy. Besides 
the studies that reported only mild-moderate elevations in 
liver enzymes of HCV positive patients with hematological 
malignancy undergoing chemotherapy (Zuckerman et al., 
1998), in a recent review of 160 non-Hodgkin lymphoma 
patients with chronic hepatitis C, it was reported that 15% 
of them had significant liver toxicity (Arcaini et al., 2010). 
Also in diffuse large B-cell lymphoma patients, it was 
shown that, overall survival was significantly worse in the 
patients with chronic HCV infection than those without 
HCV infection (at a median follow up of two years overall 
survival rates were 56% and 80% respectively and p 0.02) 
(Besson et al., 2006). Still it seems that more studies 
are needed in this aspect. In our study we didn’t detect 
any hepatic failure or delay of chemotherapy because of 
hepatitis, in HCV positive patients.
In conclusion, not only for hematological malignancies 
but also for solid tumors, screening for HBV and HCV is 
required before the start of chemotherapy. Prophylactic 
antiviral therapy for HBV reduces both the reactivation 
rates and HBV related mortality and morbidity. For HCV 
infection in patients receiving chemotherapy, uncertainty 
still exists.
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